Daniel Santos

1.5k total citations
47 papers, 996 citations indexed

About

Daniel Santos is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Daniel Santos has authored 47 papers receiving a total of 996 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Genetics, 25 papers in Pathology and Forensic Medicine and 20 papers in Immunology. Recurrent topics in Daniel Santos's work include Chronic Lymphocytic Leukemia Research (41 papers), Lymphoma Diagnosis and Treatment (25 papers) and Immunodeficiency and Autoimmune Disorders (13 papers). Daniel Santos is often cited by papers focused on Chronic Lymphocytic Leukemia Research (41 papers), Lymphoma Diagnosis and Treatment (25 papers) and Immunodeficiency and Autoimmune Disorders (13 papers). Daniel Santos collaborates with scholars based in United States, France and Greece. Daniel Santos's co-authors include Steven P. Treon, Zachary R. Hunter, Andrew R. Branagan, Kenneth C. Anderson, Lian Xu, Olivier Tournilhac, Evdoxia Hatjiharissi, Robert Manning, Xavier Leleu and Christopher J. Patterson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Daniel Santos

44 papers receiving 977 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Santos United States 14 556 511 462 223 217 47 996
Timothy J. Murphy United States 9 778 1.4× 399 0.8× 799 1.7× 158 0.7× 192 0.9× 19 1.2k
Marie‐Christine Kyrtsonis Greece 18 497 0.9× 177 0.3× 421 0.9× 471 2.1× 376 1.7× 81 1.1k
Antonis Dagklis Italy 15 511 0.9× 411 0.8× 443 1.0× 124 0.6× 230 1.1× 25 866
Domenico Levato Italy 20 674 1.2× 387 0.8× 461 1.0× 205 0.9× 309 1.4× 29 974
Silvia Zibellini Italy 13 629 1.1× 242 0.5× 459 1.0× 223 1.0× 154 0.7× 29 761
Nathalie Gachard France 18 354 0.6× 397 0.8× 565 1.2× 401 1.8× 311 1.4× 57 1.3k
Simar Pal Singh Netherlands 9 387 0.7× 337 0.7× 235 0.5× 152 0.7× 226 1.0× 14 793
Laurens P. Kil Netherlands 11 456 0.8× 386 0.8× 271 0.6× 140 0.6× 232 1.1× 14 811
Ruth de Tute United Kingdom 11 513 0.9× 309 0.6× 373 0.8× 379 1.7× 272 1.3× 28 871
Claudia Fazi Italy 12 583 1.0× 368 0.7× 397 0.9× 172 0.8× 192 0.9× 20 804

Countries citing papers authored by Daniel Santos

Since Specialization
Citations

This map shows the geographic impact of Daniel Santos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Santos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Santos more than expected).

Fields of papers citing papers by Daniel Santos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Santos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Santos. The network helps show where Daniel Santos may publish in the future.

Co-authorship network of co-authors of Daniel Santos

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Santos. A scholar is included among the top collaborators of Daniel Santos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Santos. Daniel Santos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Desbois, Mélanie, Thierry Giffon, Kevin C. Hart, et al.. (2025). IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells. Cancer Immunology Research. 13(8). 1172–1189. 1 indexed citations
2.
Leleu, Xavier, Zachary R. Hunter, Lian Xu, et al.. (2009). Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. British Journal of Haematology. 145(1). 59–63. 13 indexed citations
3.
Hatjiharissi, Evdoxia, Lian Xu, Daniel Santos, et al.. (2007). Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism. Blood. 110(7). 2561–2564. 215 indexed citations
4.
Leleu, Xavier, Kelly O’Connor, Allen W. Ho, et al.. (2006). Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. American Journal of Hematology. 82(1). 83–84. 27 indexed citations
5.
Hatjiharissi, Evdoxia, Allen W. Ho, Lian Xu, et al.. (2006). Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenstrom’s Macroglobulinemia (WM).. Blood. 108(11). 2490–2490. 2 indexed citations
6.
Santos, Daniel, Evdoxia Hatjiharissi, Olivier Tournilhac, et al.. (2006). CD52 Is Expressed on Human Mast Cells and Is a Potential Therapeutic Target in Waldenström's Macroglobulinemia and Mast Cell Disorders. Clinical Lymphoma & Myeloma. 6(6). 478–483. 34 indexed citations
7.
Tournilhac, Olivier, Daniel Santos, Lian Xu, et al.. (2006). Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Annals of Oncology. 17(8). 1275–1282. 87 indexed citations
8.
Ho, Allen W., Xavier Leleu, Evdoxia Hatjiharissi, et al.. (2005). A Novel Functional Role for Soluble CD27 in the Pathogenesis of Waldenstrom’s Macroglobulinemia.. Blood. 106(11). 4701–4701. 4 indexed citations
9.
Hunter, Zachary R., Andrew R. Branagan, Robert Manning, et al.. (2005). CD5, CD10, and CD23 Expression in Waldenström's Macroglobulinemia. Clinical Lymphoma. 5(4). 246–249. 40 indexed citations
10.
Treon, Steven P., Zachary R. Hunter, Abha Aggarwal, et al.. (2005). Characterization of familial Waldenström's macroglobulinemia. Annals of Oncology. 17(3). 488–494. 124 indexed citations
11.
Tai, Yu‐Tzu, Xianfeng Li, Tong Xia, et al.. (2005). Human Anti-CD40 Antagonist Antibody Triggers Significant Antitumor Activity against Human Multiple Myeloma. Cancer Research. 65(13). 5898–5906. 115 indexed citations
12.
13.
Tassone, Pierfrancesco, Paola Neri, Jeffery L. Kutok, et al.. (2005). A SCID-hu in vivo model of human Waldenstrom macroglobulinemia. Blood. 106(4). 1341–1345. 29 indexed citations
14.
15.
Hunter, Zachary R., Andrew R. Branagan, Daniel Santos, et al.. (2004). High Levels of Soluble Immunoregulatory Receptors in Patients with WaldenstroM’s Macroglobulinemia.. Blood. 104(11). 4881–4881. 6 indexed citations
16.
Treon, Steven P., Olivier Tournilhac, Andrew R. Branagan, et al.. (2004). Clinical Responses to Sildenafil in Waldenstrom’s Macroglobulinemia.. Blood. 104(11). 4926–4926. 2 indexed citations
17.
Treon, Steven P., Olivier Tournilhac, Andrew R. Branagan, et al.. (2004). Clinical Responses to Sildenafil in Waldenstrom's Macroglobulinemia. Clinical Lymphoma. 5(3). 205–207. 18 indexed citations
18.
Branagan, Andrew R., et al.. (2004). Characterization of familial Waldenstrom's Macroglobulinemia. Journal of Clinical Oncology. 22(14_suppl). 6558–6558. 2 indexed citations
19.
Tournilhac, Olivier, Daniel Santos, Andrew R. Branagan, et al.. (2004). Excess bone marrow mast cells constitutively express CD154 (CD40 ligand) in Waldenstrom's macroglobulinemia and may support tumor cell growth through CD154/CD40 pathway. Journal of Clinical Oncology. 22(14_suppl). 6555–6555. 3 indexed citations
20.
Treon, Steven P., et al.. (2004). Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Annals of Oncology. 15(10). 1481–1483. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy J. Murphy Breakdown of academic impact, for papers by Marie‐Christine Kyrtsonis Breakdown of academic impact, for papers by Antonis Dagklis Breakdown of academic impact, for papers by Domenico Levato Breakdown of academic impact, for papers by Silvia Zibellini Breakdown of academic impact, for papers by Nathalie Gachard Breakdown of academic impact, for papers by Simar Pal Singh Breakdown of academic impact, for papers by Laurens P. Kil Breakdown of academic impact, for papers by Ruth de Tute Breakdown of academic impact, for papers by Claudia Fazi
Rankless by CCL
2026